We are grateful to Janina Kuhl, Nadine Chelius, Petra Kussmann, Lena Willnow and Dorothee Lenhard for excellent technical assistance.

All animal experiments were performed in accordance with local ethical and legal guidelines of&#160;Regierungspr&#228;sidium Freiburg Referat 35.
1. Reagent Preparation
NOTE: Before starting the experiment, prepare the following reagents from the dissociation kit:
<ol>
	<li>To prepare enzyme H dissolve each vial of the lyophilized powder in 3 ml of RPMI 1640 Roswell Park Memorial Institute 1640 (RPMI 1640) or Dulbecco&#39;s modified Eagle medium (DMEM). In order to avoid repeated freezing and thawing prepare suitable aliquots (e.g., 200 &#181;l) and store them at - 20 &#176;C for up to 6 months.</li>
	<li>To prepare enzyme R dissolve the vial of the lyophilized powder in 2.7 ml of RPMI or DMEM medium. In order to avoid repeated freezing and thawing prepare suitable aliquots (e.g., 100 &#181;l) and store them at - 20 &#176;C for up to 6 months.</li>
	<li>To prepare enzyme A dissolve the vial of the lyophilized powder in 1 ml of Buffer A supplied with the kit without vortexing. In order to avoid repeated freezing and thawing prepare suitable aliquots (e.g., 25 &#181;l) and store them at - 20 &#176;C for up to 6 months. Make sure to thoroughly mix this suspension immediately before withdrawing the required reaction volume.</li>
	<li>Prepare 250 ml buffer (1x&#160; PBS with 0.5% BSA) for cell separation procedure and antibody staining. 
	NOTE: When culturing cells after removal of mouse cells filter all buffers and enzyme solutions through a 0.22 &#181;m filter.</li>
</ol>
2. Tumor Dissociation Protocol
NOTE: In this study patient-derived xenografts of non-small cell lung cancer (NSCLC), renal cancer and bladder were used. The tumors were generated by implanting xenografts of non-small cell lung cancer (NSCLC) renal cancer and bladder in 4 - 6 weeks old female NMRI nu/nu mice as described previously13. 
NOTE: As this protocol is completely independent of the tumor type, it can be used for any kind of patient or cell line-derived tumor as well as other types of human xenotransplanted tissue without modification of the protocol.
<ol>
	<li>Prepare 5 ml of digestion mix per tissue sample (up to 1 g) freshly by adding 4.7 ml of RPMI 1640 or DMEM, 200 &#181;l of enzyme H, 100 &#181;l of enzyme R, and 25 &#181;l of enzyme A into a cellular dissociation tube (C Tube). Make sure to thoroughly mix enzyme R suspension before withdrawing the required volume.</li>
	<li>Sacrifice the animals by cervical dislocation under anesthesia. Disinfect mouse by spraying with small amount of 80% v/v ethanol.</li>
	<li>Harvest subcutaneous tumor from the mouse flank using forceps and scissors in a tissue culture hood. Cut the skin open in place of the tumor using scissors and then separate the tumor from adjacent healthy tissue using forceps and scissors. 
	NOTE: Depending of the purpose of the experiment perform this and following steps under aseptic conditions. In this study all steps were carried out in a cell culture hood under aseptic conditions in order to being able to cultivate the cells.</li>
	<li>Prepare the tumor sample for digestions by removing fat (as this will make the sample float) and necrotic areas (as this will result in decreased viability) by cutting it away using forceps and a scalpel. Mince the tissue into pieces of 2 - 4 mm by using scalpels and forceps.</li>
	<li>Transfer the tissue pieces into the C Tube containing the digestion mix.</li>
	<li>Close the C Tube and make sure it is tightly closed. Attach it upside down onto the sleeve of the benchtop tissue dissociator and make sure that the tissue pieces are located in the area of the rotor/stator.</li>
	<li>Choose the mode &#34;h_tumor_01&#34; by pressing the &#34;up&#34; or &#34;down&#34; button until the mode appears in the display and then pressing the &#34;start&#34; button.
	<ol>
		<li>If using the heating function of the benchtop tissue dissociator, make sure to also attach the heater. Then run mode 37C_h_TDK_1 (for soft tumors), 37C_h_TDK_2 (for medium tumors) or 37C_h_TDK_3 (for hard tumors) by clicking the folder symbol on the touchscreen until the folder &#34;Miltenyi&#34; appears.</li>
		<li>To choose the mode, click the up or down arrow until the dissociation mode 37C_h_TDK_2 is highlighted. The sleeves of the benchtop tissue dissociator are depicted as positions on the display of the device. Choose the positions samples are run on by clicking them on the touchscreen. Press &#34;start&#34; to run the mode and continue with step 2.16. 
		NOTE: Depending on the tumor type another dissociation program might be suitable (see step 2.7.1).</li>
	</ol>
	</li>
	<li>Observe a window showing &#34;Termination of the program&#34; on the screen. After termination of the program, detach C Tube from the benchtop tissue dissociator.</li>
	<li>Incubate sample for 30 min at 37 &#176;C under continuous rotation, e.g., by using a tube rotator.</li>
	<li>After incubation attach C Tube upside down onto the sleeve of the benchtop tissue dissociator. Again make sure that the sample material is located in the area of the rotor/stator.</li>
	<li>Run the dissociation program h_tumor_02 (for soft and medium tumors) or h_tumor_01 (for hard tumors) as described in step 2.7.1.</li>
	<li>After termination of the program, detach C Tube from the benchtop tissue dissociator.</li>
	<li>Incubate sample for 30 min at 37 &#176;C under continuous rotation.</li>
	<li>Attach C Tube upside down onto the sleeve of the benchtop tissue dissociator after incubation. Again make sure that the sample material is located in the area of the rotor/stator.</li>
	<li>Run the dissociation program h_tumor_03 (for soft tumors), h_tumor_02 (for medium tumors) or h_tumor_01 (for hard tumors) as described in step 2.7.</li>
	<li>To collect the sample material at the tube bottom perform a short centrifugation step (at 100 x g for 10 sec).</li>
	<li>Resuspend the cells and apply to a cell strainer with 70 &#181;m nesh size placed on a 50 ml tube. Wash the cell strainer with 20 ml of RPMI 1640 or DMEM.</li>
	<li>Centrifuge cell suspension at 300 x g for 7 min. Aspirate supernatant completely.</li>
	<li>Resuspend cells in 5 ml of buffer for counting. Proceed with Mouse Cell Depletion by magnetic cell separation (section 3).</li>
</ol>
3. Mouse Cell Depletion by Magnetic Cell Separation Technology
NOTE: Volumes for magnetic labeling given below are for up to 2 x 106 tumor cells or 107 total cells including red blood cells. Depending on the tumor size lower or higher cell numbers will be obtained. In case of fewer cells, use the same volumes as indicated. When using higher cell numbers, scale up all reagent volumes and total volumes accordingly (e.g., for 4 x 106 tumor cells or 2 x 107 total cells, use twice the volume of all indicated reagent volumes and total volumes).
<ol>
	<li>Determine cell number of an aliquot from cell suspension in step 2.21 using a microscope and suitable chamber for counting. 
	NOTE: At this point the cell suspension consists of a heterogeneous mixture of human tumor cells as well as mouse stromal and blood cells, including red blood cells. The composition of the cells strongly depends on tumor type and region for transplantation.</li>
	<li>When performing flow cytometric analysis after removal of mouse cells withdraw 100 &#181;l aliquots to suitable tubes for an unstained and two single color control staining&#39;s for flow cytometric analysis. Store them in a refrigerator at 2 - 8 &#176;C until further staining steps (section 4).</li>
	<li>Centrifuge cell suspension at 300 x g for 10 min. Discard the supernatant.</li>
	<li>Resuspend cell pellet in 80 &#181;l of buffer per 2 x 106 tumor cells or 107 total cells Add 20 &#181;l of the magnetic labeling reagent for mouse cells.</li>
	<li>Mix well and incubate for 15 min in the refrigerator (2 - 8 &#176;C). During magnetic labeling, prepare large scale columns (LS columns) for magnetic separation, by placing it in the magnetic field of a suitable magnet (see Table of Materials and Equipment) according to the manufacturer&#39;s protocol. Rinse the column with 3 ml of buffer.</li>
	<li>Adjust the sample volume to 500 &#181;l using buffer for up to 2 x 106 tumor cells or up to 107 total cells. (Up to 1 x 107 tumor cells or up to 5 x 107 total cells can be processed on one LS Column. When working with more cells split the sample onto multiple LS Columns).
	<ol>
		<li>When performing flow cytometric analysis, molecular analysis or comparing fractions in cultures, withdraw a 50 &#181;l aliquot as unsorted sample. Store it in a refrigerator at 2 - 8 &#176;C until further processing.</li>
	</ol>
	</li>
	<li>Apply 500 &#181;l of the cell suspension onto the previously prepared column. Collect flow-through containing unlabeled target cells, representing the enriched human tumor cells. 
	NOTE: When working with higher cell numbers up to 2.5 ml of cell suspension that was prepared according to step 3.5 can be applied to one column.</li>
	<li>Wash column with 2 x 1 ml of buffer. Collect the cells that pass through and combine with the flow-through from step 3.6. Perform washing steps by adding the 1 ml buffer aliquots as soon as the column reservoir is empty. 
	NOTE: The flow-through contains purified human tumor cells.</li>
	<li>To also collect the mouse cells retained in the column, remove column from the separator and place it on a suitable tube. Pipette 3 ml of buffer onto the column and immediately use the plunger to flush out the mouse cells by firmly pushing it into the column.</li>
	<li>Spin down the fractions and control samples at 300 x g for 10 min. Aspirate supernatant completely and resuspend cells in buffer, culture medium or freeze pellet in liquid nitrogen, depending on the desired downstream application.</li>
</ol>
4. Downstream Analyses
<ol>
	<li>Staining for Flow Cytometric Analysis 
	NOTE: Before carrying out further downstream analyses, a part of cells obtained from mouse cell depletion procedure can be analyzed (e.g., assess purity and yield) in flow cytometry.
	<ol>
		<li>For flow cytometric analyses, spin at least 10% of negative and positive fraction obtained from magnetic cell separation procedure (section 3) as well as the control samples from step 3.2 and 3.5 at 300 x g for 10 min.</li>
		<li>Discard the supernatant. Resuspend the cell pellet of the staining control samples from step 3.2 in 90 &#181;l of buffer. Resuspend the fractions obtained from magnetic cell separation procedure in 80 &#181;l of buffer.</li>
		<li>Add 10 &#181;l of mouse FcR Blocking Reagent to all samples. Mix well and incubate for 5 min at 2 - 8 &#176;C in a refrigerator.</li>
		<li>Add 10 &#181;l of anti-human EpCAM-PE (equals antibody dilution of 1:10) and 25 &#181;l of anti-mouse-APC cocktail (equals antibody dilution of 1:4) to the samples from section 3. Add 10 &#181;l of anti-human EpCAM-PE to one single color control sample (equals antibody dilution of 1:10) and 10 &#181;l of anti-human EpCAM-APC to the other (equals antibody dilution of 1:10). Mix all samples and incubate for 10 min at 2 - 8 &#176;C in a refrigerator. 
		NOTE: EpCAM is not suitable as tumor cell marker of any tumor type. For the tumors used in this study EpCAM expression was known.</li>
		<li>To wash the samples, add 1 ml of buffer each and spin at 300 x g for 5 min.</li>
		<li>Discard the supernatant and resuspend the cell pellet to a concentration for flow cytometric analysis. To exclude dead cells add propidium iodide (1 &#181;g/ml).</li>
		<li>Perform flow cytometric analysis using a suitable flow cytometer according to manufacturer&#39;s protocols.</li>
	</ol>
	</li>
	<li>Cultivation of Human Tumor Cells 
	NOTE: In addition to flow cytometry, cells obtained from the separation procedure can be cultured and used for further assays in vitro.
	<ol>
		<li>Resuspend the sorted fraction from section 3 in culture medium to a concentration of 5 x 105 cells/ml. 
		NOTE: Depending on the tumor type coating, suitable seeding density, and cultivation conditions can differ.</li>
		<li>Add 500 &#181;l of cell suspension into the wells of a 24 well plate coated with 0.1% gelatin.</li>
		<li>Incubate cells in a cell culture incubator at 37 &#176;C and 5%. 
		NOTE: Optimal culture conditions depend on the tumor type used. Therefore, apply culture conditions suitable for the tumor type used.</li>
	</ol>
	</li>
	<li>Immunofluorescence Staining of Cultured Cells
	<ol>
		<li>Prepare blocking solution by adding 10% FCS and 0.1% Triton X-100 to 1x PBS.</li>
		<li>Discard culture medium. Add 500 &#181;l of 1x PBS per well to wash cells. Incubate for 2 min at room temperature (RT), then discard 1x PBS completely.</li>
		<li>Fix cells by adding 300 &#181;l of 4% PFA solution. Incubate at RT for 15 min.</li>
		<li>Discard PFA solution. Wash fixed cells 3 times as indicated in step 4.3.2.</li>
		<li>Perform permeabilization and blocking by adding 300 &#181;l of blocking per well. Incubate at RT for 30 min.</li>
		<li>Discard blocking solution. Wash cells as indicated in step 4.3.2.</li>
		<li>Add 300 &#181;l of primary antibody diluted in blocking solution to the cells. Anti-human EpCAM antibody is diluted 1:40, Vimentin antibody is diluted 1:200. Incubate overnight at 2 - 8 &#176;C. 
		Note: The antibodies used are not suitable for any tumor type as EpCAM might not be expressed on tumor cells and/or vimentin is also expressed by the tumor cells. Make sure the antibodies used are suitable for the xenograft model.</li>
		<li>Discard primary antibody solution. Wash cells 3 times as indicated in step 4.3.2.</li>
		<li>Add 300 &#181;l of secondary antibody diluted in blocking solution to the cells. Both antibodies, anti-rabbit IgG-Alexe594 and anti-mouse IgG-Alexa488 are diluted 1:400. Incubate for 1 hr in the dark at RT.</li>
		<li>Discard secondary antibody solution. Wash cells 2 times as indicated in step 4.3.2.</li>
		<li>Add 300 &#181;l of DAPI solution (0.1 &#181;g/ml) to each well. Incubate for 10 min in the dark at RT.</li>
		<li>Discard DAPI solution. Wash cells 3 times as indicated in step 4.3.2.</li>
		<li>Add 500 &#181;l of 1x PBS to each well. Perform fluorescence microscopy using a suitable microscope.</li>
	</ol>
	</li>
	<li>Whole Exome Sequencing
	<ol>
		<li>For Whole exome sequencing (WES) freeze pellets from step 3.9 in liquid nitrogen. Store and collect samples at -80 &#176;C.</li>
		<li>After collecting the cells, perform exome capturing and whole exome sequencing in accordance to manufacturer&#39;s instructions of the respective kit (see Table of Materials and Equipment).</li>
	</ol>
	</li>
</ol>

<ol>
	<li>Daniel, V. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+primary+xenograft+model+of+small-cell+lung+cancer+reveals+irreversible+changes+in+gene+expression+imposed+by+culture+in+vitro.">A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.</a> Cancer Res. 69 (8), 3364-3373 (2009).</li><li>Tentler, J. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Patient-derived+tumour+xenografts+as+models+for+oncology+drug+development.">Patient-derived tumour xenografts as models for oncology drug development.</a> Nat Rev Clin Oncol. 9 (6), 338-350 (2012).</li><li>DeRose, Y. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+grafts+derived+from+women+with+breast+cancer+authentically+reflect+tumor+pathology,+growth,+metastasis+and+disease+outcomes.">Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.</a> Nat Med. 17 (11), 1514-1520 (2011).</li><li>Siolas, D., Hannon, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Patient-derived+tumor+xenografts:+transforming+clinical+samples+into+mouse+models.">Patient-derived tumor xenografts: transforming clinical samples into mouse models.</a> Cancer Res. 73 (17), 5315-5319 (2013).</li><li>Wong, S. Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeted-capture+massively-parallel+sequencing+enables+robust+detection+of+clinically+informative+mutations+from+formalin-fixed+tumours.">Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.</a> Sci Rep. 3, 3494 (2013).</li><li>Sausville, E. A., Burger, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Contributions+of+human+tumor+xenografts+to+anticancer+drug+development.">Contributions of human tumor xenografts to anticancer drug development.</a> Cancer Res. 66 (7), 3351-3354 (2006).</li><li>Rubio-Viqueira, B., Hidalgo, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Direct+in+vivo+xenograft+tumor+model+for+predicting+chemotherapeutic+drug+response+in+cancer+patients.">Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.</a> Clin Pharmacol Ther. 85 (2), 217-221 (2009).</li><li>Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A., Bongso, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Embryonic+stem+cell+lines+from+human+blastocysts:+somatic+differentiation+in+vitro.">Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro.</a> Nat Biotechnol. 18 (4), 399-404 (2000).</li><li>Merk, J., Rolff, J., Becker, M., Leschber, G., Fichtner, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Patient-derived+xenografts+of+non-small-cell+lung+cancer:+a+pre-clinical+model+to+evaluate+adjuvant+chemotherapy.">Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy.</a> Eur J Cardiothorac Surg. 36 (3), 454-459 (2009).</li><li>Baiocchi, M., Biffoni, M., Ricci-Vitiani, L., Pilozzi, E., De Maria, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=New+models+for+cancer+research:+human+cancer+stem+cell+xenografts.">New models for cancer research: human cancer stem cell xenografts.</a> Curr Opin Pharmacol. 10 (4), 380-384 (2010).</li><li>Gires, O., Stoecklein, N. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Dynamic+EpCAM+expression+on+circulating+and+disseminating+tumor+cells:+causes+and+consequences.">Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences.</a> Cell Mol Life Sci. 71 (22), 4393-4402 (2014).</li><li>Zhang, C. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synergistic+effect+of+the+gamma-secretase+inhibitor+PF-03084014+and+docetaxel+in+breast+cancer+models.">Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.</a> Stem Cells Transl Med. 2 (3), 233-242 (2013).</li><li>Boven, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phase+II+preclinical+drug+screening+in+human+tumor+xenografts:+a+first+European+multicenter+collaborative+study.">Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.</a> Cancer Res. 52 (21), 5940-5947 (1992).</li><li>Agorku, D., Hardt, O., Bosio, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Depletion of mouse cells from human tumor xenografts significantly reduces bias in molecular analysis and improves culture of target cells. Abstract 95. , (2014).</li><li>Agorku, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Next-generation sequencing of human tumor xenografts is significantly improved by prior depletion of mouse cells. Abstract 1455. , (2015).</li><li>Bolger, A. M., Lohse, M., Usadel, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Trimmomatic:+a+flexible+trimmer+for+Illumina+sequence+data.">Trimmomatic: a flexible trimmer for Illumina sequence data.</a> Bioinformatics. 30 (15), 2114-2120 (2014).</li><li>Li, H., Durbin, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fast+and+accurate+short+read+alignment+with+Burrows-Wheeler+transform.">Fast and accurate short read alignment with Burrows-Wheeler transform.</a> Bioinformatics. 25 (14), 1754-1760 (2009).</li><li>Koboldt, D. C., Larson, D. E., Wilson, R. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Using+VarScan+2+for+Germline+Variant+Calling+and+Somatic+Mutation+Detection.">Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection.</a> Curr Protoc Bioinformatics. 44, (2013).</li><li>Robinson, J. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Integrative+genomics+viewer.">Integrative genomics viewer.</a> Nat Biotechnol. 29 (1), 24-26 (2011).</li><li>Aloia, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+sialyl-glycolipid+stage-specific+embryonic+antigen+4+marks+a+subpopulation+of+chemotherapy-resistant+breast+cancer+cells+with+mesenchymal+features.">The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.</a> Breast Cancer Res. 17 (1), 146 (2015).</li></ol>

David Agorku, Stefan Tomiuk, Stefan Wild, Silvia R&#252;berg, Lisa Zatrieb, Andreas Bosio and Olaf Hardt are or were employees of Miltenyi Biotec GmbH, Germany. Kerstin Klingner and Julia Sch&#252;ler are employees of Oncotest GmbH, Germany.

We have developed a fast and easy method to isolate untouched human tumor cells from xenografted tumor tissue. This procedure is based on the comprehensive depletion of cells of mouse origin by combining automated tissue dissociation and magnetic cell sorting. Besides depletion of all mouse cells also the amount of dead cells and debris is significantly reduced in the target cell fraction. Taken together, this method significantly improves molecular downstream analyses and cultivation of human tumor cells.
In contrast to alternative methods, there is no need for knowledge of tumor cell specific markers, adjustment to varying compositions of mouse cells or establishment of algorithms. The presented method is independent of the mouse strain and tumor type. Therefore, a bias through isolation of human tumor subpopulations on the basis of single human specific markers which may vary in expression, as shown for EpCAM11, is avoided. Furthermore, it is not limited to tumor material but can be used for any kind of xenotransplanted tissue as mouse cells are targeted instead of specific human tumor subpopulations (data not shown).
Comprehensive removal of mouse cells is facilitated by targeting surface epitopes exclusively expressed on cells of mouse origin. Apart from the well-established method for tumor dissociation as presented in this study, there are many procedures using different kinds of enzymes. Preservation of cell surface epitopes is a prerequisite for this novel method, but also for accurate analyses of human tumor cell populations. Therefore, it is crucial that gentle enzymes are used for digestion of tumor tissue. Thus, mouse cell depletion can only be used in combination with enzymatic digestion procedures that evidently do not affect epitopes targeted during mouse cell depletion procedure. In case of doubt this can only be verified by the respective manufacturer.
This method also works for human circulating tumor cells (CTCs). However, as frequencies of target cells are usually &#60; 0.1% removal of mouse cells additionally requires red blood cell lysis and purities of more than 50% cannot be expected. In this case, mouse cell depletion can be used as pre-enrichment of CTCs followed by an enrichment using positive markers (data not shown).
Removal of mouse cells significantly improves the culture of human tumor cells by avoiding culture overgrow of mouse fibroblasts. In addition, the analysis of human tumor xenografts by next-generation sequencing is significantly improved and standardized. As this effect was observed although a targeted human sequence-specific selection has been carried out during exome enrichment, the influence on whole genome and whole transcriptome sequencing are expected to be even more prominent.
Moreover, the presented method facilitates accurate molecular studies of tumor subpopulations within xenotransplanted human tumors. Removal of mouse cells from a respective sample in the first step and subsequently sorting human tumor cells in two different subpopulations enables direct molecular comparison of the tumor subpopulation of interest to human bulk tumor cells20. Differential gene expression between tumor cell subtypes can be more reliably assessed as it is not affected by cross-hybridization of mouse-derived molecules.

Solid human tumors consist of multiple physiological as well as neoplastic cell types. They form heterogeneous tissues with complex biological structures. Biological processes like tumor formation, progression and responses towards therapies are not yet fully understood. In vitro cell culture models represent a useful tool to study and understand tumor biology. However, they can only partly mirror structures and processes found in tumor tissues. Reliable and stable preclinical human tumor models are a prerequisite for the development of anti-tumor drugs and therapies4,6 as well as for understanding tumor biology and the interaction of tumor cells and their environment.
Human tumor xenograft models derived from primary patient tumors show high relations to the tissue of origin regarding histological architecture, interactions with micro-environmental structures, metastatic potential and responses to drugs7. Even when tumor xenografts are derived from cultured cells or cell lines they more closely mimic patient tumors, therefore showing higher validity in most assays compared to in vitro cell culture models. These features make them the gold standard of preclinical models4. Besides its application in cancer research, xenotransplantation of human cells into mice is also frequently used in stem cell research to determine the stemness and differentiation potential of a target population8.
It has been shown that human microvasculature and human immune cells are replaced upon in vivo propagation of human tumors2,9. Factors such as the tumor subtype, growth rate, and region of transplantation have major impacts on the global level of infiltration as well as the composition of the mouse cell types found. However, even when these factors are kept constant, the amount and composition of mouse cells are highly variable.
Downstream analyses of xenografted tissues are often challenged by cells of murine origin. Primary cultures of human tumor cells from xenografts are frequently overgrown by fibroblasts. Besides hampering the generation of tumor cell lines in vitro, downstream assays such as drug cytotoxicity testing or pharmacokinetics are biased since in silico correction for effects originating from contaminating mouse cells is impossible in most cases. Beyond that, the only partly elucidated cross-talk between mouse fibroblasts and human tumor cells has a direct impact on experimental outcomes of studies10. Furthermore, the most widely unpredictable variation of infiltrating mouse cells aggravates accurate molecular downstream analyses. In NGS or proteome analyses each mouse-derived signal measured instead of a human tumor signal directly decreases sequencing sensitivity. Also microarray based expression analyses are challenged by murine nucleic acids possibly cross hybridizing to human probes.
In order to circumvent the obstacles of contaminating mouse cells in downstream analyses of human tumor cells from xenograft models different approaches have been proposed. In many studies desired target cells for downstream analysis are isolated by utilizing markers or combinations of markers exclusively expressed on human tumor cells. However, the lack of reliable markers for positive identification of human tumor cells frequently represents a big hurdle. Even broadly expressed markers, such as EpCAM on human carcinomas, frequently show tumor intrinsic expression differences11. This increases the risk that low expressing subpopulations, e.g., tumor cells undergone epithelial-to-mesenchymal transition, are lost during isolation. In addition, the direct binding of a selection agent to the target cell might influence the subsequent analysis results. Attempts of depleting mouse cells by using a combination of antibodies specific for murine CD45 and MHC class I epitopes have also been made12. However, this marker combination only detects a subset of mouse cells. Another approach is to enhance analyzing processes by software. Nevertheless, all these approaches are either not suitable for any kind of experimental setup or for any tumor entity and transplantation method.
In this study we present a novel and fast method for comprehensively depleting mouse cells from xenografted tissues independent of the mouse strain and tissue of origin. In screenings on multiple target organs and tissues for transplantation of xenografts (including skin, lung, brain, kidney and skeletal muscle) we were able to identify a combination of antibodies allowing for comprehensively detecting mouse cells. These antibodies were coupled to superparamagnetic particles, titrated and optimized for depletion by using magnetic cell sorting. As only mouse specific antibodies are used, human target cells stay &#34;untouched&#34; and the method is not limited to xenotransplanted tumor tissue. We demonstrate that comprehensively removing mouse cells from xenografted tumor samples standardizes and facilitates cultures of human tumor cells. Furthermore, we show that the analysis of human tumor xenografts by next generation sequencing is significantly improved. As this effect was observed although a human sequence specific selection has been carried out during exome enrichment, the influence on whole genome and whole transcriptome sequencing are expected to be even more prominent. Taken together, removal of mouse cells using this novel method facilitates cultivation of human tumor cells and significantly improves the downstream analyses of human tumor xenografts.

<table><tbody><tr><td>Tumor Dissociation Kit, human</td><td>Miltenyi Biotec</td><td>130-095-929</td><td>contains enzymes H, R and A; see data sheet for reconstitution instructions</td></tr><tr><td>RPMI 1640</td><td>Biowest</td><td>L0501-500</td><td></td></tr><tr><td>gentleMACS C-Tubes</td><td>Miltenyi Biotec</td><td>130-096-334</td><td></td></tr><tr><td>gentleMACS Octo Dissociator with Heaters</td><td>Miltenyi Biotec</td><td>130-096-427</td><td></td></tr><tr><td>MACS SmartStrainer (70 &amp;micro;m)</td><td>Miltenyi Biotec</td><td>130-098-462</td><td></td></tr><tr><td>Petri dish 100 mm</td><td>Various</td><td></td><td></td></tr><tr><td>Scalpel</td><td>Various</td><td></td><td></td></tr><tr><td>Mouse Cell Depletion Kit</td><td>Miltenyi Biotec</td><td>130-104-694</td><td></td></tr><tr><td>PBS</td><td>Various</td><td></td><td>use 1x PBS for PEB buffer</td></tr><tr><td>EDTA</td><td>Sigma-Aldrich</td><td>3610</td><td>use final concentration of 2 mM in PEB buffer</td></tr><tr><td>BSA</td><td>Miltenyi Biotec</td><td>130-091-376</td><td>or use 5 mg/L BSA in PEB buffer</td></tr><tr><td>MACS LS columns</td><td>Miltenyi Biotec</td><td>130-042-401</td><td></td></tr><tr><td>QuadroMACS Separator</td><td>Miltenyi Biotec</td><td>130-090-976</td><td></td></tr><tr><td>MACS MultiStand</td><td>Miltenyi Biotec</td><td>130-042-303</td><td></td></tr><tr><td>PreSep filters (70 &amp;micro;m)</td><td>Miltenyi Biotec</td><td>130-095-823</td><td></td></tr><tr><td>MACSmix Tube Rotator</td><td>Miltenyi Biotec</td><td>130-090-753</td><td></td></tr><tr><td>CD326-FITC, human</td><td>Miltenyi Biotec</td><td>130-080-301</td><td>use 1:40 for immunofluorescence staining&amp;nbsp;</td></tr><tr><td>anti-Vimentin antibody</td><td>abcam</td><td>ab92547</td><td></td></tr><tr><td>goat-anti-mouse IgG-Alexa488</td><td>Life Technologies</td><td>A11029</td><td></td></tr><tr><td>goat-anti-rabbit IgG-Alexa594</td><td>Life Technologies</td><td>A11012</td><td></td></tr><tr><td>DAPI</td><td>Sigma-Aldrich</td><td>D9542</td><td>dilute to a final concentration of 0.1 &amp;micro;g/ml in 0.1 M sodium bicarbonate&amp;nbsp;</td></tr><tr><td>Inside Stain Kit</td><td>Miltenyi Biotec</td><td>130-090-477</td><td>InsideFix from this kit can be used for fixation step during immunofluorescence staining&amp;nbsp;</td></tr><tr><td>FBS</td><td>Various</td><td></td><td></td></tr><tr><td>Triton X-100&amp;nbsp;</td><td>Sigma-Aldrich</td><td>93418</td><td></td></tr><tr><td>FcR Blocking Reagent, mouse</td><td>Miltenyi Biotec</td><td>130-092-575</td><td></td></tr><tr><td>Gelatin</td><td>Sigma-Aldrich</td><td>G2500-100g</td><td></td></tr><tr><td>Nextera Rapid Capture Enrichment Kit</td><td>Illumina</td><td>FC-140-1000</td><td></td></tr><tr><td>MiSeq Reagent Kit v3</td><td>Illumina</td><td>MS-102-3001</td><td></td></tr></tbody></table>

depletion of mouse cells from human tumor xenografts significantly improves downstream analysis of target cells

The use of in vitro cell line models for cancer research has been a useful tool. However, it has been shown that these models fail to reliably mimic patient tumors in different assays1. Human tumor xenografts represent the gold standard with respect to tumor biology, drug discovery, and metastasis research 2-4. Tumor xenografts can be derived from different types of material like tumor cell lines, tumor tissue from primary patient tumors4 or serially transplanted tumors. When propagated in vivo, xenografted tissue is infiltrated and vascularized by cells of mouse origin. Multiple factors such as the tumor entity, the origin of xenografted material, growth rate and region of transplantation influence the composition and the amount of mouse cells present in tumor xenografts. However, even when these factors are kept constant, the degree of mouse cell contamination is highly variable.
Contaminating mouse cells significantly impair downstream analyses of human tumor xenografts. As mouse fibroblasts show high plating efficacies and proliferation rates, they tend to overgrow cultures of human tumor cells, especially slowly proliferating subpopulations. Mouse cell derived DNA, mRNA, and protein components can bias downstream gene expression analysis, next-generation sequencing, as well as proteome analysis 5. To overcome these limitations, we have developed a fast and easy method to isolate untouched human tumor cells from xenografted tumor tissue. This procedure is based on the comprehensive depletion of cells of mouse origin by combining automated tissue dissociation with the benchtop tissue dissociator and magnetic cell sorting. Here, we demonstrate that human target cells can be can be obtained with purities higher than 96% within less than 20 min independent of the tumor type.

Different approaches have been proposed to identify or deplete mouse cells from xenografted human tumors, for example a combination of mouse-specific antibodies against CD45 and MHC class I. However, only subpopulations of mouse cells were detected using these combinations whereas the proposed combination detected CD45 and MHC class I expressing mouse cells as well as the rest of the mouse cells found in target tissues for transplantation (Figure 1). Utilizing this novel combination of antibodies for magnetic cell sorting, human tumor cells could be isolated independent of tumor type (Figure 2).
Cells obtained from magnetic cell separation procedure-based mouse cell removal could be cultured, leading to pure cultures of human tumor cells (Figure 4). In addition, viable mouse cells could be obtained and cultured from the same sample. Besides removal of mouse cells, also debris was removed upon mouse cell depletion (MCD) (Figure 3).
The comprehensive depletion of mouse cells as well as debris removal lead to improved molecular downstream analyses. This was demonstrated by comparing results obtained from whole exome sequencing (WES) carried out on bulk tumor pieces and mouse cell depleted samples from three different patient-derived xenograft tumor models (Figures 5 - 9). Our data indicate that the removal of mouse cells before performing WES on xenograft tumor samples not only significantly increases the total amount of reads (Figure 5) but also considerably reduces the number of host derived reads mapped to the human reference genome (Figure 6B). As these erroneously mapped mouse reads frequently interfere with SNP calling, we observed a strong reduction of falsely predicted SNPs after MCD (Figures 7 - 8). Finally, we showed that the in silico removal of mouse-derived reads by bioinformatics methods could not fully replace the experimental procedure, as an unambiguous sequence-based assignment to the species of origin was not possible for all reads. Furthermore, the in silico procedure could not correct for the enhanced quality and concomitant higher read coverage of the in vitro depleted samples (Figure 9).
<img alt="Figure 1" src="/files/ftp_upload/54259/54259fig1.jpg" /> 
Figure 1. Establishing an Antibody Cocktail Recognizing All Mouse Cells across Multiple Organs14. Screenings in multiple organs, including skin, lung, brain, kidney and skeletal muscle, have been performed. These organs represent major target tissues for xenotransplantation. Combinations such as those recognizing mouse CD45 and MHC class I epitopes have already been used in order to deplete mouse cells after xenotransplantation. However, these marker combinations recognized only a subset of mouse cells in all analyzed tissues. In previous screenings a combination of five antibodies has been identified allowing for the comprehensive detection of all cells from mouse origin. This panel includes red blood cells and is independent of the tissue of origin (A, B, and data not shown). Modified from14. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" src="/files/ftp_upload/54259/54259fig2.jpg" /> 
Figure 2. Reliable and Fast Depletion of Mouse Cells15. Conjugates of the antibody combination with superparamagnetic nanoparticles were used to develop an optimized protocol for depletion of mouse cells from human tumor xenografts by magnetic cell sorting (magnetic cell separation) (A). This novel protocol allowed for the elimination of &#62; 99% of contaminating mouse cells in less than 20 min, irrespective of the tumor type. Cell fractions obtained from magnetic cell separation procedure were labeled with the pan-mouse antibody cocktail and a human specific antibody against CD326 (EpCAM) (B). Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 3" src="/files/ftp_upload/54259/54259fig3.jpg" /> 
Figure 3. Isolation of Human Glioblastoma Cells. Mouse Cell Depletion Kit was used to isolate human glioblastoma cells from adult mouse brain. During dissociation of neural tissue high amounts of debris is commonly generated. MCDK efficiently depletes dead cells and debris as seen by the plot showing cell size versus cell granularity. With this conjugate cocktail, it was possible to eliminate &#62; 99% of the contaminating mouse cells and &#62; 60% of the debris. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 4" src="/files/ftp_upload/54259/54259fig4.jpg" /> 
Figure 4. Depletion of Mouse Cells Facilitates Downstream Cultures of Human Tumor Cells14. Mouse fibroblasts frequently hamper the cultivation of human tumor cells after dissociation of transplanted tissues or lead to heterogeneous cultures. Fibroblasts attach and expand more efficiently, thereby overgrowing target cells. This perturbs in vitro cell culture assays (e.g., drug cytotoxicity testing), since mathematical correction for effects arising from contaminating mouse cells is impossible in most cases. The negative (B) and positive fractions (C) after mouse cell depletion were cultured for three days, fixed and stained for a mouse-specific fibroblast marker (Vimentin) and the human-specific tumor marker CD326 (EpCAM). As a control, the original fraction containing unseparated cells (A) was cultured and stained as well. Even after three days of culture, a nearly pure population of human tumor cells was observed in the negative fraction (B), whereas the unsorted fraction (A) was almost overgrown by fibroblasts. Only a minor portion of target cells was lost to the positive fraction (C). Modified from14. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig4large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 5" src="/files/ftp_upload/54259/54259fig5.jpg" /> 
Figure 5. Whole Exome Sequencing (WES) of Tumor Samples Prior to and after Mouse Cell Depletion (MCD)15. We conducted WES on three different xenograft models derived from human kidney, lung and bladder cancer in order to assess the impact of MCD on the quality of next-generation sequencing data. DNA from bulk tumor and from isolated tumor cells after mouse cell depletion was used to generate exome-captured sequencing libraries applying an exome capture kit. For sequencing on a desktop sequencer instrument, a desktop sequencer reagent kit 150 cycles, was utilized to generate 75-bp paired-end reads. A significant increase (p &#60; 0.05) in cluster density (A) as well as an average increase in read counts of 33% (B) was observed for the samples depleted of mouse cells, indicating improved sample quality. Correspondingly, a strong reduction of debris and dead cells upon MCD could also be demonstrated by flow cytometry analysis (see Figure 3). Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig5large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 6" src="/files/ftp_upload/54259/54259fig6.jpg" /> 
Figure 6. Mouse Cell Depletion (MCD) Strongly Reduces Number of Erroneously Mapped Mouse Reads after Whole Exome Sequencing (WES)15. As capture oligonucleotides used for targeted enrichment of protein-coding sequences were designed based on the human genome, an initial pre-enrichment of DNA fragments of human origin from the mixture of mouse and human cells was expected. In order to assess the number of capture oligonucleotides that might cross-hybridize with mouse genomic DNA, we conducted BLAST searches of each single rapid capture exome probe against mouse genome. The resulting alignment parameters were used to determine possible cross-hybridization. Depending on the selection thresholds (alignment length, no. of mismatches, no. of gaps), we predicted a cross-reactivity of 5 - 10% of capture probes with mouse transcripts (data not shown). After adapter clipping (trimmomatic v0.3216), we mapped the reads of all samples against human and mouse genomes (bwa v0.7.1217) and determined their putative origin based on the respective alignment parameters (LINUX shell, command-line Perl) (A). An average of 12% of reads derived from bulk tumor samples was attributed to mouse cells. This amount could be reduced to 0.3% by prior depletion of mouse cells (B). As on average 15% of the mouse-derived reads mapped erroneously to the human genome, corresponding to 1.9% of total reads in the bulk tumor samples and 0.04% in the isolated tumor cells, a strong positive influence of mouse cell depletion on downstream analyses can be expected. Figure 6B exemplifies the detailed read assignment for bulk tumor and isolated human tumor cells derived from the bladder cancer xenograft. Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig6large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 7" src="/files/ftp_upload/54259/54259fig7.jpg" /> 
Figure 7. MCD Strongly Reduces the Number of Falsely Predicted SNPs15. In order to determine the impact of mouse reads mapped to the human genome, we determined the number of predicted SNPs for the xenograft samples prior to and after MCD. As no healthy tissue was available for comparison, a SNP was defined as a difference between the sequenced sample and the reference genome (hg19). After removal of duplicate reads, SNP and INDEL calling was conducted18 and was restricted to the regions targeted by an exome capture kit. 63 &#177; 10% of all SNPs predicted for the bulk tumor samples were no longer detected after mouse cell depletion, 18 &#177; 1% were specific for the isolated human tumor cells (A). While the former were mainly caused by erroneously mapped mouse reads the latter seemed to be detected due to higher read counts and accordingly higher coverage within the isolated human tumor cell samples. This effect was also visible for predicted INDELs (B). Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig7large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 8" src="/files/ftp_upload/54259/54259fig8.jpg" /> 
Figure 8. MCD Improves the Prediction of High-impact SNPs15. (A) Impact of MCD on SNP prediction within a protein-coding exon of the POLA1 gene19 is exemplified. While erroneously mapped mouse reads caused a number of falsely predicted SNPs in the bulk kidney cancer xenograft, these SNPs were missing after MCD. In addition, MCD also improved the prediction of high-impact SNPs. For example, mouse reads mapped to the human reference genome in the bulk tumor sample resulted in the wrongly predicted destruction of the start codon of the GRIA3 gene (B). Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig8large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 9" src="/files/ftp_upload/54259/54259fig9.jpg" /> 
Figure 9. In Silico Depletion of Mouse-derived Reads Cannot Fully Replace In Vitro MCD15. The reads predicted to be of mouse origin were computationally removed from the sequencing data, and SNP calling was repeated. By this approach, the number of SNPs predicted for the bulk tumor samples was considerably reduced from 63% to 8.5% of the total number of SNPs (compare with Figure 8). However, this in silico approach could not completely replace in vitro MCD, especially if the improved sample quality and the concomitant increase in read counts and coverage are considered. Modified from15. <a href="https://www.jove.com/files/ftp_upload/54259/54259fig9large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

Watch this Scientific Journal Video about Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells at JoVE.com

Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells

Human tumor xenografts are vascularized and infiltrated by cells of mouse origin during the growth phase in vivo. To circumvent the bias caused by these contaminating cells during downstream analysis, we developed a method allowing for comprehensive depletion of all mouse cells by magnetic cell sorting.

The use of in vitro cell line models for cancer research has been a useful tool. However, it has been shown that these models fail to reliably mimic ...

depletion-mouse-cells-from-human-tumor-xenografts-significantly

Research

JoVE Journal

Medicine

12.6K Views.  Miltenyi Biotec GmbH.  Humane tumor xenotransplantaten zijn gevasculariseerd en geïnfiltreerd door cellen van muizen oorsprong tijdens de groeifase in vivo. Om de voorspanning door deze contaminerende cellen tijdens downstream analyse te omzeilen, hebben wij een methode waardoor uitgebreide depletie van muizencellen door magnetische celsortering. 

Video: Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Patient derived tumor xenograft (PDTX) models provide a necessary platform in facilitating anti-cancer drug development prior to human trials. Human tumor pieces are injected subcutaneously into athymic nude mice (immunocompromised, T cell deficient) to create a bank of tumors and subsequently are passaged into different generations of mice in order to maintain these tumors from patients. Importantly, cellular heterogeneity of the original tumor is closely emulated in this model, which provides a more clinically relevant model for evaluation of drug efficacy studies (single agent and combination), biomarker analysis, resistant pathways and cancer stem cell biology. Some limitations of the PDTX model include the replacement of the human stroma with mouse stroma after the first generation in mice, inability to investigate treatment effects on metastasis due to the subcutaneous injections of the tumors, and the lack of evaluation of immunotherapies due to the use of immunocompromised mice. However, even with these limitations, the PDTX model provides a powerful preclinical platform in the drug discovery process.

Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.

Patient derived tumor xenograft (PDTX) models provide a necessary platform in facilitating anti-cancer drug development prior to human trials. Human tumor ...

Cancer Research

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

B lymphocytes are key players in immune cell circulation and they mainly home to and reside in lymphoid organs. While normal B cells only proliferate when stimulated by T lymphocytes, oncogenic B cells survive and expand autonomously in undefined organ niches. Mantle cell lymphoma (MCL) is one such B cell disorder, where the median survival rate of patients is 4 - 5 years. This calls for the need of effective mechanisms by which the homing and engraftment of these cells are blocked in order to increase the survival and longevity of patients. Therefore, the effort to develop a xenograft mouse model to study the efficacy of MCL therapeutics by blocking the homing mechanism in vivo is of utmost importance. Development of animal recipients for human cell xenotransplantation to test early stage drugs have long been pursued, as relevant preclinical mouse models are crucial to screen new therapeutic agents. This animal model is developed to avoid human graft rejection and to establish a model for human diseases, and it may be an extremely useful tool to study disease progression of different lymphoma types and to perform preclinical testing of candidate drugs for hematologic malignancies, like MCL. We established a xenograft mouse model that will serve as an excellent resource to study and develop novel therapeutic approaches for MCL.

Mantle cell lymphoma (MCL) is a difficult to treat B cell disorder and it is equally difficult to establish a xenograft mouse model of primary MCL to study and develop therapeutics. Here, we describe the successful establishment of MCL xenografts in mice to help understand its underlying biology.

B lymphocytes are key players in immune cell circulation and they mainly home to and reside in lymphoid organs. While normal B cells only proliferate when ...

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

The discovery and development of immuno-oncology (I-O) therapy in recent years represents a milestone in the treatment of cancer. However, treatment challenges persist. Robust and disease-relevant animal models are vital resources for continued preclinical research and development in order to address a range of additional immune checkpoints. Here, we describe a human peripheral blood mononuclear cell (PBMC) &#8212; based humanized xenograft model. BGB-A317 (Tislelizumab), an investigational humanized anti-PD-1 antibody in late-stage clinical development, is used as an example to discuss platform set-up, model characterization and drug efficacy evaluations. These humanized mice support the growth of most human tumors tested, thus allowing the assessment of I-O therapies in the context of both human immunity and human cancers. Once established, our model is comparatively time- and cost-effective, and usually yield highly reproducible results. We suggest that the protocol outlined in this article could serve as a general guideline for establishing mouse models reconstituted with human PBMC and tumors for I-O research.

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

We describe a human peripheral blood mononuclear cell (PBMC) &#8212; based humanized xenograft mouse model for translational immuno-oncology research. This protocol could serve as a general guideline for establishing and characterizing similar models for I-O therapy assessment.

The discovery and development of immuno-oncology (I-O) therapy in recent years represents a milestone in the treatment of cancer. However, treatment ...

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

In vivo experimental models of hepatocellular carcinoma (HCC) that recapitulate the human disease provide a valuable platform for research into disease pathophysiology and for the preclinical evaluation of novel therapies. We present a variety of methods to generate subcutaneous or orthotopic human HCC xenografts in immunodeficient mice that could be utilized in a variety of research applications. With a focus on the use of primary tumor tissue from patients undergoing surgical resection as a starting point, we describe the preparation of cell suspensions or tumor fragments for xenografting. We describe specific techniques to xenograft these tissues i) subcutaneously; or ii) intrahepatically, either by direct implantation of tumor cells or fragments into the liver, or indirectly by injection of cells into the mouse spleen. We also describe the use of partial resection of the native mouse liver at the time of xenografting as a strategy to induce a state of active liver regeneration in the recipient mouse that may facilitate the intrahepatic engraftment of primary human tumor cells. The expected results of these techniques are illustrated. The protocols described have been validated using primary human HCC samples and xenografts, which typically perform less robustly than the well-established human HCC cell lines that are widely used and frequently cited in the literature. In comparison with cell lines, we discuss factors which may contribute to the relatively low chance of primary HCC engraftment in xenotransplantation models and comment on technical issues that may influence the kinetics of xenograft growth. We also suggest methods that should be applied to ensure that xenografts obtained accurately resemble parent HCC tissues.

Human tumor xenografts in immunodeficient mice are valuable tools to study cancer biology. Specific protocols to generate subcutaneous and intrahepatic xenografts from human hepatocellular carcinoma cells or tumor fragments are described. Liver regeneration induced by partial hepatectomy in recipient mice is presented as a strategy to facilitate intrahepatic engraftment.

In  vivo experimental models of hepatocellular carcinoma (HCC) that recapitulate  the human disease provide a valuable platform for research into disease  ...

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Our laboratory has developed a novel orthotopic implantation model of human prostate cancer (PCa). As PCa death is not due to the primary tumor, but rather the formation of distinct metastasis, the ability to effectively model this progression pre-clinically is of high value. In this model, cells are directly implanted into the ventral lobe of the prostate in Balb/c athymic mice, and allowed to progress for 4-6 weeks. At experiment termination, several distinct endpoints can be measured, such as size and molecular characterization of the primary tumor, the presence and quantification of circulating tumor cells in the blood and bone marrow, and formation of metastasis to the lung. In addition to a variety of endpoints, this model provides a picture of a cells ability to invade and escape the primary organ, enter and survive in the circulatory system, and implant and grow in a secondary site. This model has been used effectively to measure metastatic response to both changes in protein expression as well as to response to small molecule therapeutics, in a short turnaround time.

This orthotopic model of human prostate cancer allows for quantification of tumor size, circulating tumor cells, and formation of distinct metastasis to the lung. As cells must escape the primary organ, enter the blood stream, and implant into a secondary site, this model effectively recapitulates the scenario in humans.

Our laboratory has developed a novel orthotopic implantation model of  human prostate cancer (PCa). As PCa death is not due to the primary tumor, but  ...

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine cancer models are extremely limited in their diversity and suffer from poor translation to the clinic. To serve as a more physiological preclinical model for immunotherapy studies, this protocol has been developed to evaluate the treatment of human tumors in a mouse reconstituted with a human immune system. This unique protocol demonstrates the development of human immune system (HIS, &#34;humanized&#34;) mice, followed by implantation of a human tumor, either a cell-line derived xenograft (CDX) or a patient derived xenograft (PDX). HIS mice are generated by injecting CD34+ human hematopoietic stem cells isolated from umbilical cord blood into neonatal BRGS (BALB/c Rag2-/- IL2R&#947;C-/- NODSIRP&#945;) highly immunodeficient mice that are also capable of accepting a xenogeneic tumor. The importance of the kinetics and characteristics of the human immune system development and tumor implantation is emphasized. Finally, an in-depth evaluation of the tumor microenvironment using flow cytometry is described. In numerous studies using this protocol, it was found that the tumor microenvironment of individual tumors is recapitulated in HIS-PDX mice; &#34;hot&#34; tumors exhibit large immune infiltration while &#34;cold&#34; tumors do not. This model serves as a testing ground for combination immunotherapies for a wide range of human tumors and represents an important tool in the quest for personalized medicine.

This protocol outlines the generation of human immune system (HIS) mice for immuno-oncology studies. Instructions and considerations in the use of this model for testing human immunotherapeutics on human tumors implanted in this model are presented with an emphasis on characterizing the response of the human immune system to the tumor.

Reversing the immunosuppressive nature of the tumor microenvironment is critical for the successful treatment of cancers with immunotherapy drugs. Murine ...

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Neutrophils, the most abundant of all white blood cells in the human circulation, play an important role in the host defense against invading microorganisms. In addition, neutrophils play a central role in the immune surveillance of tumor cells. They have the ability to recognize tumor cells and induce tumor cell death either through a cell contact-dependent mechanism involving hydrogen peroxide or through antibody-dependent cell-mediated cytotoxicity (ADCC). Neutrophils with anti-tumor activity can be isolated from peripheral blood of cancer patients and of tumor-bearing mice. These neutrophils are termed tumor-entrained neutrophils (TEN) to distinguish them from neutrophils of healthy subjects or na&#239;ve mice that show no significant tumor cytotoxic activity. Compared with other white blood cells, neutrophils show different buoyancy making it feasible to obtain a &#62; 98% pure neutrophil population when subjected to a density gradient. However, in addition to the normal high-density neutrophil population (HDN), in cancer patients, in tumor-bearing mice, as well as under chronic inflammatory conditions, distinct low-density neutrophil populations (LDN) appear in the circulation. LDN co-purify with the mononuclear fraction and can be separated from mononuclear cells using either positive or negative selection strategies. Once the purity of the isolated neutrophils is determined by flow cytometry, they can be used for in vitro and in vivo functional assays. We describe techniques for monitoring the anti-tumor activity of neutrophils, their ability to migrate and to produce reactive oxygen species, as well as monitoring their phagocytic capacity ex vivo. We further describe techniques to label the neutrophils for in vivo tracking, and to determine their anti-metastatic capacity in vivo. All these techniques are essential for understanding how to obtain and characterize neutrophils with anti-tumor function.

Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.

Neutrophils, the most abundant of all white blood cells in the human circulation, play an important role in the host defense against invading ...

Immunology and Infection

Primary Tumor and MEF Cell Isolation to Study Lung Metastasis

In breast tumorigenesis, the metastatic stage of the disease poses the greatest threat to the affected individual. Normal breast cells with altered genotypes now possess the ability to invade and survive in other tissues. In this protocol, mouse mammary tumors are removed and primary cells are prepared from tumors. The cells isolated from this procedure are then available for gene profiling experiments. For successful metastasis, these cells must be able to intravasate, survive in circulation, extravasate to distant organs, and survive in that new organ system. The lungs are the typical target of breast cancer metastasis. A set of genes have been discovered that mediates the selectivity of metastasis to the lung. Here we describe a method of studying lung metastasis from a genetically engineered mouse model.. Furthermore, another protocol for analyzing mouse embryonic fibroblasts (MEFs) from the mouse embryo is included. MEF cells from the same animal type provide a clue of non-cancer cell gene expression. Together, these techniques are useful in studying mouse mammary tumorigenesis, its associated signaling mechanisms and pathways of the abnormalities in embryos.

The goal of this protocol is to study breast tumorigenesis. With this technique, mouse mammary tumors are removed and primary cells are prepared from tumors. A lung extraction protocol is included for studying lung metastasis. Furthermore, another protocol for analyzing mouse embryonic fibroblasts from the mouse embryo is included.

In breast tumorigenesis, the metastatic stage of the disease poses the greatest threat to the affected individual. Normal breast cells with altered ...

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Patient derived xenograft (PDX) models are gaining popularity in cancer research and are used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. Circulating tumor cells (CTC) play a critical role in tumor metastasis and have been isolated from patients with several tumor types. Recently, CTCs have been used to generate PDX experimental models of breast and prostate cancer. This manuscript details the method for the generation of prostate cancer PDX models from CTCs developed by our group. Advantages of this method over conventional PDX models include independence from surgical sample collection and generating experimental models at various disease stages. Density gradient centrifugation followed by red blood cell lysis and flow cytometry depletion of CD45 positive mononuclear cells is used to enrich CTCs from peripheral blood samples collected from patients with metastatic disease. The CTCs are then injected into immunocompromised mice; subsequently generated xenografts can be used for functional studies or harvested for molecular characterization. The primary limitation of this method is the negative selection method used for CTC enrichment. Despite this limitation, the generation of PDX models from CTCs provides a novel experimental model to be applied to prostate cancer research.

This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.

Patient derived xenograft (PDX) models are gaining popularity in cancer research and are used for preclinical drug evaluation, biomarker identification, ...

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research, including cancer research. A gene-of-interest can be added or deleted from a mouse&#8217;s genome using genetic engineering techniques, and if it causes tumor initiation in mice, it is highly likely to be a cancer-critical gene in humans. In addition, mouse models such as reporter mice can also be used to study the crucial stages of tumor initiation and their progression to aggressive cancers. In such mice, a reporter gene with luminescence or fluorescence tags is inserted into the cells under study to monitor their growth and proliferation.
Pre-clinical studies in mouse models serve as a perfect step between in vitro studies on cell cultures and clinical studies in humans. They can be used for investigating in vivo pharmacokinetics, toxicity, and anti-tumor efficacy of numerous chemotherapeutic agents before any of the drugs go to clinical trials. However, since mouse tumor cells or immune responses may not exactly represent the tumorigenic process in humans, mouse models have been developed that can closely mimic the tumor progression and immune responses in humans, for example, human tumor xenografts in immunocompromised mice or humanized mouse models.
In vivo testing in animals, including mice, can often raise ethical concerns. While it is true that experimentation in animals causes suffering, the benefits of animal experimentation in drug discovery are undeniable. Therefore, animal studies should be strictly avoided wherever alternative testing methods are available. In addition, experiments on animals should only be conducted after in vitro studies have been successfully performed on suitable cell lines.

Mouse Models of Cancer and Pre-clinical Testing of Cancer Drugs

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are ...

Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells

Samenvatting

Meer video's verkennen